Cargando…

iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Shashank, Jirásko, Michal, Lochman, Jan, Chvátal, Alexandr, Chottova Dvorakova, Magdalena, Kučera, Radek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500601/
https://www.ncbi.nlm.nih.gov/pubmed/36143270
http://dx.doi.org/10.3390/jpm12091485
_version_ 1784795260308684800
author Pandey, Shashank
Jirásko, Michal
Lochman, Jan
Chvátal, Alexandr
Chottova Dvorakova, Magdalena
Kučera, Radek
author_facet Pandey, Shashank
Jirásko, Michal
Lochman, Jan
Chvátal, Alexandr
Chottova Dvorakova, Magdalena
Kučera, Radek
author_sort Pandey, Shashank
collection PubMed
description In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson’s disease scored highest, followed by Alzheimer’s disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine.
format Online
Article
Text
id pubmed-9500601
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95006012022-09-24 iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine Pandey, Shashank Jirásko, Michal Lochman, Jan Chvátal, Alexandr Chottova Dvorakova, Magdalena Kučera, Radek J Pers Med Review In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson’s disease scored highest, followed by Alzheimer’s disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine. MDPI 2022-09-10 /pmc/articles/PMC9500601/ /pubmed/36143270 http://dx.doi.org/10.3390/jpm12091485 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pandey, Shashank
Jirásko, Michal
Lochman, Jan
Chvátal, Alexandr
Chottova Dvorakova, Magdalena
Kučera, Radek
iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title_full iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title_fullStr iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title_full_unstemmed iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title_short iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
title_sort ipscs in neurodegenerative disorders: a unique platform for clinical research and personalized medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500601/
https://www.ncbi.nlm.nih.gov/pubmed/36143270
http://dx.doi.org/10.3390/jpm12091485
work_keys_str_mv AT pandeyshashank ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine
AT jiraskomichal ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine
AT lochmanjan ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine
AT chvatalalexandr ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine
AT chottovadvorakovamagdalena ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine
AT kuceraradek ipscsinneurodegenerativedisordersauniqueplatformforclinicalresearchandpersonalizedmedicine